Imaging Biomarkers of Progression of Mobility Impairment in Parkinson Disease

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

67 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-05-31

Study Completion Date

2015-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research is to evaluate changes in cholinergic brain activity over time in subjects with Parkinson disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Imaging Studies of Cognitive Impairment in Parkinson s Disease

NCT01862744

Parkinson Disease Dementia

COMPLETED

Imaging Biomarkers in Parkinson s Disease

NCT01496599

Parkinson Disease

COMPLETED

Neuroplasticity in Parkinson's Disease

NCT05286736

Parkinson Parkinson Disease

RECRUITING

Vestibulopathy, Imbalance, and Gait Disturbances in Parkinson Disease

NCT05446194

Parkinson Disease

COMPLETED NA

Innovative Biomarkers in de Novo Parkinson's Disease

NCT03940677

Parkinson's Disease Healthy Controls Group - Age and Sex-matched

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The project will apply positron emission tomography (PET) of acetylcholinesterase to study non-dopaminergic (i.e. cholinergic) brain changes over time in subjects with Parkinson disease. Acetylcholinesterase PET imaging was used to assess cholinergic changes over time in this study. Acetylcholinesterase PET imaging is a diagnostic test as the investigator does not assign specific interventions to the subjects of the study based on the acetylcholinesterase PET. Therefore, this is an observational study as defined as following: studies in human beings in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Subjects in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the subjects of the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1 Parkinson disease subjects

Subjects with Parkinson disease who previously participate in a motor and brain PET (brain positron emission tomography) imaging study who were invited for a longitudinal observational study.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who meet the UK Parkinson's Disease Society Brain Bank Research Center clinical diagnostic criteria for PD.
* Hoehn and Yahr stages 1-2.5 at initial recruitment in baseline study.
* Absence of dementia confirmed by neuropsychological testing at initial recruitment in baseline study.